

Pharmaceutical POOL

Mark **ALTMEYER**

Otsuka America Selects Former BMS Executive as CEO



Otsuka America Pharmaceutical (OAPI) has appointed Mark Altmeyer as president and CEO. Mr. Altmeyer succeeds interim President and CEO Dean Haubrich, Ph.D., who has been named

chairman of the OAPI board.

Mr. Altmeyer joins OAPI from Bristol-Myers Squibb, where he spent 16 years promoting and developing neuroscience, oncology, and metabolic/cardiovascular brands, most recently as senior VP, global commercialization for oncology. He received an MBA from Harvard Business School.

OAPI, the North American arm of Japan's Otsuka Pharmaceutical Co. Ltd., is a healthcare company that commercializes Otsukadiscovered and other product opportunities in North America.

Enrique **CONTERNO**

New President at Lilly USA



Eli Lilly has promoted Enrique Conterno to president of Lilly USA LLC, succeeding Deirdre Connelly, who recently joined Glaxo-SmithKline as president of its North American pharma-

ceuticals business. Mr. Conterno first joined Lilly in 1992 as a sales representative and most recently served as senior VP of healthcare professional markets for Lilly in the United States. He holds an MBA from Duke University.

Dr. Matthew **WIKLER**

OneWorld Health Appoints Medical Chief



The Institute for OneWorld Health, a nonprofit pharmaceutical company that develops drugs for people living in the developing world who are afflicted by neglected infectious diseases,

has named Matthew Wikler, M.D., MBA, FIDSA, chief medical officer.

Most recently, Dr. Wikler served as president and CEO of Pacific Beach BioSciences. Dr. Wikler received an M.D. from Temple University and an MBA from the Wharton School of the University of Pennsylvania.

Biotechnology POOL

Matthew **EMMENS**

Former Shire CEO Joins Vertex as President



Biotechnology company Vertex Pharmaceuticals has named a successor to Founder. President, CEO, and Chairman Joshua Boger, Ph.D. Matthew Emmens, recently joined Vertex as pres-

ident, will assume the roles of CEO and chairman upon Dr. Boger's retirement in May. Mr. Emmens was previously CEO of Shire.

Dr. Lex **VAN DER PLOEG**

Abraxis Health Expands Management

Global biotechnology company Abraxis

BioScience has named Lex Van der Ploeg, Ph.D., as senior VP of integrative medicine and translational science at its spinoff, Abraxis Health.

Dr. Van der Ploeg is responsible for building and integrating Abraxis Health's evidenced-based medicine capabilities, drug-discovery efforts, and external partnerships that serve as the foundation through which the spinoff will deliver personalized healthcare to patients.

Dr. Van der Ploeg was most recently VP, basic research, and site head for Merck Research Laboratories' Boston-based facility. He received an M.S. in biochemistry from the University of Amsterdam and a Ph.D. in biochemistry/enzymology/genetics from the University of Amsterdam/Netherlands Cancer Research Center.

Biopharmaceutical **POOL**

Dr. Frida **GRYNSPAN**

Human Cell Therapy Expert Assumes Research VP Role at Pluristem



Pluristem Therapeutics, a biotherapeutics company dedicated to the commercialization of unrelated donor-patient cell therapy products for a variety of disorders, has named Frida

Grynspan, Ph.D., VP of research and development.

Dr. Grynspan has more than a decade of extensive professional experience in the field of human cell therapy, most recently as VP of R&D for a pioneering cell-therapy company in Israel. She earned a Ph.D. in chemistry/biochemistry from the University of Illinois at Chicago and a postdoctoral degree from Harvard Medical School/McLean Hospital.

Maria **LUSK**

Eden Biodesign Expands U.S. Operations

Eden Biodesign, a U.K.-based provider of biopharmaceutical process development and cGMP manufacturing services, has appointed Maria Lusk director of client management at its U.S. subsidiary, Eden Biodesign Inc.

Most recently, Ms. Lusk was project man-



ager and business development manager at PharmaDirections.

Ms. Lusk's appointment marks the formal establishment of Eden's U.S. project management function and

coincides with the subsidiary's recent relocation to expanded facilities in Research Triangle Park, N.C.

Vincent MIHALIK

Former Lilly VP Joins Amylin Leadership Team



Amylin Pharmaceuticals has named Vincent Mihalik, senior VP, sales and marketing and chief commercial officer.

Amylin is a biopharmaceutical company committed

to improving lives through the discovery, development, and commercialization of innovative medicines.

Mr. Mihalik oversees marketing and sales for Amylin's two marketed injectable diabetes therapies, Byetta and Symlin.

He also oversees the launch and commercialization of its lead compound, a once-weekly formulation of Byetta's active ingredient exenatide.

Mr. Mihalik was previously Eli Lilly's VP of global brand development, diabetes and endocrine platform team leader.

Dr. Stephen

SHREWSBURY

AVI BioPharma Hires Chief Medical Officer



AVI BioPharma has named Stephen Shrewsbury, M.D., chief medical officer and senior VP of clinical and regulatory affairs.

AVI BioPharma is a biopharmaceutical company

developing RNA-based drugs for a wide range of diseases and genetic disorders.

Dr. Shrewsbury's 30-year career has spanned medical practice, research, clinical development, and product commercialization.

Most recently, Dr. Shrewsbury served as chief medical officer and senior VP, clinical development and regulatory affairs, for Adamas Pharmaceuticals.

He qualified at the University of Liverpool's School of Medical Education.

Specialty **POOL**

Dr. Lance **BERMAN**

Former Pfizer Executive Joins CPEX Pharmaceuticals as Medical Chief



CPEX Pharmaceuticals has named Lance Berman, M.D., chief medical officer. CPEX is an emerging specialty pharmaceutical company focused on the development, licensing, and

commercialization of pharmaceutical products using its validated drug-delivery platform technology.

Dr. Berman was most recently senior medical director and global medical team leader at Pfizer.

He received his bachelor of medicine and bachelor of surgery at the University of Cape Town and holds a master's degree in pharmaceutical medicine.

Emerging **POOL**

Robert **COHEN**Michael **MCCARTHY**

Osteotech Expands Senior Management Team



Osteotech, a provider of biologic products for regenerative healing, has added Robert Cohen as senior VP of tissue engineering.

He spearheads the company's efforts to translate

Osteotech's investments in technology-based therapies into innovative procedure-related products while also managing direct relationships with surgeon customers.

Mr. Cohen most recently served as chief technology officer for Pipeline Biomedical Holdings.

He holds an M.S. in engineering management and an M.S. in mechanical engineering from the New Jersey Institute of Technology, and has 25 patents and 35 publications to his credit.

Michael McCarthy has been named senior VP of sales, with responsibility for further implementing and managing a sales model



ment officer.

that incorporates distributor, channel partner, and direct sales strategies.

Mr. McCarthy also joins Osteotech from Pipeline Biomedical, where he served as chief business develop-

Drug Delivery POOL

Dr. Sarma **DUDDU**

Cephalon Appoints Head of Cima Labs



Cephalon has named Sarma Duddu, Ph.D., general manager and VP of drug delivery technologies of its drug-delivery subsidiary, Cima Labs.

Dr. Duddu leads all aspects of the Cephalon drug-delivery business at Cima.

Dr. Duddu has more than 15 years of pharmaceutical experience and has been involved in all aspects of the drug delivery business.

He most recently served as VP of pharmaceutical development at Nektar Therapeutics

Dr. Duddu earned a Ph.D. in pharmaceutics from the University of Minnesota.

Agency **POOL**

Dennis ASCIENZO
Cara BANDA
Allison FARESE
Tom FORBES
Terrence ROUSE

Staff Changes at Altum

Altum has announced a number of promotions and additions to its staff.

Altum is a CommonHealth professional advertising and promotion agency focused on the biotechnology and specialty markets.

Dennis Ascienzo has joined Altum as a group art director.







Previously, Mr. Ascienzo was employed at Becton Dickinson.

Altum has hired Cara Banda as an editor and Allison Farese as an account supervisor.

Ms. Farese is working on the launch of a new indication for a novel chemotherapy to treat several major cancer types.



Tom Forbes has been promoted to senior account executive from account exec-

He has responsibility for overseeing day-to-day responsibilities and opera-

tions for a leading biologic agent used to treat cancer.



Terrence Rouse, a CommonHealth alumnus, joins Altum as senior VP, group strategic planner.

Mr. Rouse most recently was a senior manager, market research, at Pharmion, which

was acquired in 2008 by Celgene.

Matt **BROWN**

Ignite Health Taps GSW Executive as Chief Operating Officer



Ignite Health has named Matt Brown chief operating

Ignite Health is an inVentiv Health company and marketing agency that specializes in patient-centered

medical advertising.

Mr. Brown previously served as senior VP and managing director for the Newtown, Pa., office of Ignite's fellow inVentiv network agency, GSW Worldwide.

Gail **CHAPMAN**

Photosound Announces Promotion



Photosound has promoted Gail Chapman to account director.

Photosound, a Health-STAR company, is a global medical communications and design agency serving

the pharmaceutical industry.

Bob **DEBARTOLO** Keith **HIGBEE** Steve **MARTORANA** Neelam **TEWAR**

Cadient Adds Account Staff







Cadient Group, an interactive marketing agency serving the healthcare industry, has announced four additions to its staff.

Bob DeBartolo has joined Cadient's West Conshohocken, Pa., headquarters as group account director.

Mr. DeBartolo is responsible for managing multiple account teams, as well as contributing to senior management, operations, and business development activities. He most recently oversaw and drove digital innovation for Omnicom's Das Healthcare network of agencies in the pharmaceutical and healthcare sector.

At Cadient's New York office, Keith Higbee has been named strategic engagement director, with responsibility for strategic planning related to new business projects. Mr. Higbee was previously a partner, account director, at Ogilvy & Mather.

Also in New York, Steve Martorana has been appointed account manager. Mr. Martorana joins Cadient from Photosound, where he was an account and business development manager.



Neelam Tewar has joined Cadient's New York office as senior account manager, with responsibility for working on new business development projects. Ms. Tewar previously worked at Grey

Healthcare Group.

Marilyn **GROSS** Vanessa **SYPKO**

Centron Appoints Head of **Medical Education**

Full-service medical communications agency Centron, a HealthSTAR company, has hired Marilyn Gross as an executive VP, managing director, and head of Centron's



cation practice leader for Catapult Communications. In other staff additions, Vanessa Sypko has been appointed account supervisor.

medical education group.

Ms. Gross joins Centron

from Euro RSCG Life, where she was president of Medical

Education Group and publi-

Ms. Sypko was previously account director at Advo-



Alya **SHERMAN**

CMI Announces Executive Promotion



Communications Media (CMI) has promoted Alya Sherman to VP, media services, from executive director, media strategies. CMI is an advertising, media, and promotion planning organi-

zation focused primarily on the pharmaceutical and related healthcare industry.

Michael WONG

Davies Names Pharma/Biotech Practice Head



Public affairs and strategic communications firm **Davies** has appointed Michael Wong, J.D., leader of its healthcare team's recently launched pharma/biotech practice. Mr.

Wong was most recently healthcare practice leader for GCI Group.

Dr. W. David **WOODS**

New Chief Executive at BioscriptUS



London-based Bioscriptstirling, a full-service medical communications company, has appointed W. David Woods, Ph.D., as CEO of its U.S. arm, BioscriptUS.

Dr. Woods has spent more than two decades as a medical writer, editor, and publisher, most recently serving as editor-in-chief and director of U.S. corporate relations for a United Kingdom-based medical communications company, as well as editor of the online newsletter Health Outcomes Communicator.

Dr. Woods holds a doctorate in health pol-

icy and is a fellow of the College of Physicians of Philadelphia.

CRO POOL

Stephen CIESINSKI James RURKA

Two Executives Join SRI International



SRI International, an independent, nonprofit research and development organization, has appointed Stephen Ciesinski VP of strategic business development.

Mr. Ciesinski oversees SRI's innovation partnership programs, commercial research and development business development, international offices, corporate energy initiatives, strategic marketing, and other corporate programs.

Mr. Čiesinski was most recently chairman and CEO of Laszlo Systems. He received an MBA from Stanford University.



In other moves, SRI has named James Rurka executive director, biosciences commercialization.

Mr. Rurka is leading efforts to bring SRI's pharmaceutical products and

technologies to the market through licensing and partnership agreements.

Before joining SRI, Mr. Rurka was coowner and chief business officer of privately held biotechnology firm Blanca Pharmaceuticals.

Andrew **MACGARVEY**

New U.S. President at Quanticate



Quanticate has named Andrew MacGarvey president of its U.S. operations based in Cambridge, Mass.

Quanticate is a Londonbased global biometrics clinical research organization.

In this role, Mr. MacGarvey is responsible for managing the company's initiatives in support of existing and new clients in the United States, as well as continuing to direct its global sales efforts.

Before joining Quanticate, Mr. MacGarvey served as a director at Datatrial.

Media **POOL**

Lori FLYNN
Greg JACKSON
Laura KLEIN
Carolina PETRINI
Scott WOLF

Everyday Health Promotes, Expands







Online media network Everyday Health has announced several additions and promotions. Lori Flynn has been promoted to VP of sales development.

Greg Jackson has advanced to executive VP of marketing and sales operations from senior VP of marketing.

Mr. Jackson is responsible for creating and executing marketing strategy and increasing subscriber acquisitions across the Everyday Health network.

He holds an MBA in marketing from Rutgers University.

Laura Klein has been promoted to senior VP of sales and marketing. Ms. Klein joined Everyday Health in December 2007 as VP of sales.

Carolina Petrini has joined Everyday Health as VP of research.

She is leading the effort to expand the range of measurement and effectiveness data available to clients.

Ms. Petrini was most recently senior VP of marketing solutions for the pharmaceutical and CPG verticals for comScore.



The company also has promoted Scott Wolf to executive VP of sales from senior VP of sales.

In his three years with Waterfront Media, the company that operates

Everyday Health, Mr. Wolf has built up the salesforce from a three-person group to a team of more than 60 online publishing sales professionals.

Mr. Wolf has a master's degree in marketing from New York University's Leonard N. Stern School of Business.

Evan **YOUNG**

Slack Promotes Editor to Director of E-Publishing



Evan Young has been promoted to the new position of director of e-publishing for specialty medicine for Slack. Mr. Young was previously executive editor of three Slack publications:

Endocrine Today, HemOnc Today, and Cardiology Today.

Mr. Young collaborates with editorial, special services, and sales to develop innovative opportunities and solutions in e-publishing for current Websites and for project-specific Web publishing sites. He also is responsible for building registration and increasing traffic on all sites within Slack's specialty medicine group, leading the development of e-publishing projects, and ensuring existing sites are leaders in their specialty areas.

Medical Education **POOL**

Don **OVERCASH**

Questra Med Communications Names President



Questra Med Communications has appointed Don Overcash, R.Ph., president. Questra Med Communications specializes in developing evidence-based educational programs that support

approved products and on-label indications.

Mr. Overcash has more than two decades of senior management experience in healthcare communications, most recently serving as president of Arista Marketing Associates. He holds an MBA from the Keller Graduate School of Management at DeVry University.

Service POOL

Ajit **BAID**

Research Partnership Relocates U.S. Operations

The Research Partnership has appointed



Ajit Baid as managing director for its U.S. operations and relocated its U.S. offices to Horsham, Pa.

Mr. Baid was previously a senior director of client services for Genactis. The

Research Partnership is a London-based, fullservice global market research agency dedicated to the pharmaceutical industry.

Dr. Ann **BICHSEL** Dr. Sandra FIELDER

Former MGI Pharma Directors Join Prosar

Prosar Drug Safety Call Center, a provider of adverse event processing and medical information services, has added two directors to its executive team.



Ann Bichsel, Pharm.D., has joined Prosar as director of medical information. Dr. Bichsel brings many years of pharmaceutical experience to Prosar, as well as 20 years of nursing experience. Most

recently, Dr. Bichsel was director, medical communications, at MGI Pharma.



Sandra Fielder, M.D., has been named director of pharmacovigilance. Dr. Fielder has 17 years of pharmaceutical experience, most recently as medical director, global drug safety and pharma-

covigilance, at MGI Pharma.

Ryan CARPENTIER Lisa **CLUNE**

Leadership Changes at Kaplan EduNeering

Kaplan EduNeering, a provider of compliance and knowledge management solutions, has appointed Ryan Carpentier chief



operating officer, with responsibility for leading the company's sales, marketing, business development, and product development functions. Mr. Carpentier joined EduNeering in 2005 as senior VP of sales.



Lisa Clune has been promoted to president from her previous role as senior VP and chief technology officer. Ms. Clune has been with EduNeering since 2006. before its acquisition by Kaplan. Kaplan EduNeering is part of the Kaplan Professional business unit.

Jim **GRANATO**

Wilson Health Information Names Marketing VP



Consumer insight firm Wilson Health Information (WilsonRx) has appointed Jim Granato VP of sales and marketing.

Mr. Granato is helping to lead the company's expansion

into providing marketers with relevant healthcare information, analytics, and research services that allow them to refine their strategic goals and improve their market penetration.

Mr. Granato brings a broad range of healthcare brand marketing experience in trade publishing and electronic media to WilsonRx, most recently serving as the publisher of Pharmacy Times.

Mary Anne **GREENBERG**

Alliance Healthcare Names CEO



Healthcare marketing sercompany Alliance Healthcare Information, a subsidiary of United Drug, has promoted President and Chief Operating Officer Mary Anne Greenberg to CEO.

She succeeds Jack Thorne in this position. Mr. Thorne remains chairman of Alliance Healthcare.

Dr. Jeffrey **NEW**

PSI Selects Medical Business VP



Pharmaceutical Strategic Initiatives (PSI), a provider of medical affairs strategic consulting and content development services, has hired Jeffrey New, Pharm.D., as VP of medical activities. Dr. New

most recently was director of medical and scientific affairs at Dey L.P., a subsidiary of Mylan.

Susan TORROELLA

Former Columbia MedCom CEO Joins Medex Global

Medex Global Group, a provider of trav-



el, security, and medical assistance services, has named Susan Torroella chief operating officer.

Ms. Torroella has been charged with leading the expanding company's 24-

hour global operations.

Ms. Torroella has more than 20 years of strategic management, marketing, and sales experience in the healthcare industry.

She joins Medex after seven years as CEO of Columbia MedCom Group. She received a master's degree in international management from the Thunderbird School of Global Management.

Technology **POOL**

Dr. William **HOWARD** Kristopher WIGGS

Staff Additions at Qforma



Qforma, an advanced analytics and predictive modeling company, has appointed physicist William Howard, Ph.D., as director, field operations.

Dr. Howard joins Qforma following a diverse career in multiple technical fields.

For the past eight years, Dr. Howard has developed and marketed computational lithography products for the semiconductor industry.

He received a Ph.D. as a Hertz Foundation Fellow in applied nuclear and medical physics from the Massachusetts Institute of Technology.



In other company news, Kristopher Wiggs has been appointed VP of sales, new

Mr. Wiggs has more than a decade of pharmaceutical industry sales experience,

including a stint as district manager with Organon, which is now part of Schering-Plough. ◆

Send your personnel announcements to feedback@pharmavoice.com.

SEE DIGITAL EDITION FOR BONUS CONTENT WWW.PHARMAVOICE.COM



Be at the table.

On June 17-19, leaders from the medical device, pharmaceutical, biotechnology, diagnostics and healthcare marketing worlds will convene for a sit down. *Ideas will be shared. Knowledge will be imparted. Standouts will be recognized.*

The agenda for this year's conference, *Responding to Change*, has been developed to provide marketers with the specific strategies and tactics needed to succeed when resources and marketing options are limited. Attendees will hear from speakers who've worked in Fortune 500 companies, run global brands, and implemented winning initiatives, as they share insights on how they've succeeded in building market share, relationships, and brand loyalty.

√ Visit www.HCMAthefamily.com to learn more and register today.

Pharmaceutical **POOL**

Dr. Charles **BOWDEN**Peter **TAM**

Vivus Announces Two Promotions

Vivus, a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, has promoted two of its senior executives.

Charles Bowden, M.D., has been promoted to senior director, clinical development, from director, clinical development.

Dr. Bowden has assumed responsibility for Phase III clinical studies of avanafil for the treatment of erectile dysfunction, and he continues to lead Vivus' efforts in experimental medicine.

He received an M.D. from Baylor College of Medicine.

Peter Tam has been promoted to chief operating officer from senior VP of product and corporate development.

Mr. Tam retains overall responsibility for business development, clinical and preclinical development, regulatory affairs and chemistry, manufacturing, and controls.

He received an MBA from Santa Clara University.

Dr. D. Gary **GILLILAND**

Merck Appoints Oncology Researcher

Oncology researcher and physician D. Gary Gilliland, M.D., Ph.D., has joined Merck as senior VP of Merck Research Laboratories (MRL) and oncology franchise head.

Dr. Gilliland leads the implementation of Merck's oncology research strategy and serves as a member of Merck's research management committee.

Dr. Gilliland comes to Merck after almost 20 years on the faculty at Harvard. While there, he was professor of medicine at Harvard Medical School and professor of stem cell and regenerative biology at Harvard University.

He is also an investigator of the Howard Hughes Medical Institute, director of the leukemia program at the Dana-Farber/Harvard Cancer Center, and director of the cancer stem cell program of the Harvard Stem Cell Institute.

Dr. Gilliland received his Ph.D. in microbiology from the University of California, Los Angeles.

He received his M.D. from the University of California, San Francisco.

Biotechnology POOL

Dr. Jennifer **DOUDNA**

Genentech Strengthens Research Team

Jennifer Doudna, Ph.D., has joined global biotechnology company Genentech as VP, discovery research, overseeing the departments of protein chemistry and structural biology.

In this newly created role, Dr. Doudna also serves as a member of the small molecule drug discovery senior leadership team and participates in therapeutic RNA discovery efforts

Dr. Doudna comes to Genentech from the University of California, Berkeley, where she served as a professor in the Departments of Molecular and Cell Biology and Chemistry, as well as a Howard Hughes Medical Institute investigator. She earned a Ph.D. in biochemistry from Harvard University.

Biopharmaceutical POOL

Dr. Andrew CHENG

Gilead Sciences Promotes Development VP

Gilead Sciences, a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need, has promoted Andrew Cheng, M.D., Ph.D., to senior VP, development operations, from VP, clinical research.

Dr. Cheng is responsible for Gilead's biometrics, clinical operations, drug safety and public health, project and portfolio management, and regulatory affairs activities. He received a medical degree and a Ph.D. in cellular and molecular biology from Columbia University.

William **FLETCHER**

NTI Taps Director as Acting CEO

Neurobiological Technologies (NTI) has appointed William Fletcher acting CEO, and its board has discontinued its previously announced search for a permanent, full-time president and CEO.

Mr. Fletcher has served as chairman of Teva Pharmaceuticals North America since 2004, and as a director of NTI since 2007.

Mr. Fletcher is working with NTI's board to evaluate alternatives and determine the best direction for NTI following the failure of its Viprinex program, which was in Phase III clinical trials for stroke.

David **HOLTZ**

Nucryst Selects CFO as Interim Chief Executive

Nucryst Pharmaceuticals has selected VP and Chief Financial Officer David Holtz to serve as interim president and CEO, replacing departing Chairman, President, and CEO Thomas Gardner.

Neil Carragher, currently lead director of Nucryst, has assumed the role of chairman. Mr. Holtz retains his role as chief financial officer of the company.

Nucryst develops, manufactures, and commercializes medical products that fight infection and inflammation using Silcryst, an atomically disordered nanocrystalline silver technology.

Specialty **POOL**

Chris MARIO

Neuropharm Names Brand Leader in U.S. Office

Neuropharm Group, a U.K.-based specialty pharmaceutical company focused on the development of medicines for the treatment of neurodevelopmental disorders, has appointed Chris Mario brand leader within its U.S. operating unit, Neuropharm Inc.

Ms. Mario brings to Neuropharm more than two decades of experience in pharmaceutical marketing and sales, most recently as executive director of U.S. and global marketing within Wyeth Pharmaceuticals' biopharma business unit. She joins Neuropharm as it prepares to apply for U.S. approval of NPL-2008 for the treatment of autism in the second quarter of 2009.

Dr. Bruce **MORRA**

New Chief Executive at Scolr Pharma

Scolr Pharma has appointed Bruce Morra, Ph.D., MBA, president and CEO. Scolr Pharma is a specialty pharmaceutical company that combines its formulation expertise and its patented CDT platform to develop novel pharmaceutical, over-the-counter, and nutritional products.

Dr. Morra has extensive experience in the pharmaceutical, medical device, biotechnology, and polymers industries, and has served as a member of the Scolr Pharma board of directors since August 2007. He received an MBA and a

Ph.D. in polymer science and engineering from the University of Massachusetts at Amherst

Agency **POOL**

Michael **BURCHILL**

Joel **CONSTANTZ**

Dawn MCHUGH

Doug MCINTOSH

Abby **MORRIS**

Roxane **PADGETT**

Clint **SMITH**

Chris **SONDERMAN**

GSW Adds Staff in Three Locations

Healthcare advertising agency GSW Worldwide, an inVentiv Health company, has announced a number of additions across three offices.

Michael Burchill has been named senior interactive art director for GSW's Newtown, Pa., office. Mr. Burchill previously worked for inVentiv sister agency Ignite Health as associate creative director.

At GSW's Columbus, Ohio, headquarters, Joel Constantz has been named VP, senior planner. Mr. Constantz previously served as senior VP, director of strategic planning, for Tierney Communications.

Dawn McHugh has joined GSW's New York office as VP, account director. Ms. McHugh previously served as VP, account supervisor, for Draftfcb Healthcare. She received a master's degree from Hofstra University.

Doug McIntosh has joined GSW's Columbus office as VP, account director, from the same position at The Cartel Group.

Abby Morris has been named account executive in the Columbus office. Previously, Ms. Morris was talent acquisition manager for Taylor Search Partners.

Also in Columbus, Roxane Padgett has been appointed VP, account director. Ms. Padgett was most recently global team leader for Dell. She holds a master's degree from Crown College.

In the Newtown office, Clint Smith has been named senior editor. Mr. Smith was most recently group editorial supervisor for CDM Princeton.

Chris Sonderman has been named senior brand designer in the Columbus office. Mr. Sonderman most recently served as lead creative for Swingtop.

Christine **DONNELLAN**

Navicor Adds to Creative Team

Christine Donnellan has joined the Navicor Group as associate creative director. Ms. Donnellan previously served as senior VP, group creative director, for Sudler & Hennessey. Navicor, an inVentiv Health company, is a healthcare advertising agency specializing in oncology and immunology.

Isabelle **SIMON**

New VP at Publicis Groupe

Isabelle Simon has joined Paris-based global communications group Publicis Groupe as senior VP, with responsibility for overseeing the mergers and acquisitions and legal departments, and monitoring minority holdings and the company's external development strategy.

Ms. Simon is a Harvard Law School graduate and a member of the bar in New York and Paris.

Ms. Simon also holds post-master degrees in English and North American business law and international tax law.

CRO POOL

Allen ROSENSTON

Industry Veteran Joins Halo Pharmaceutical

Specialty contract pharmaceutical manufacturer Halo Pharmaceutical has appointed Allen Rosenston VP of business development. Mr. Rosenston joins Halo after a long career at Abbott Laboratories, during which he developed Abbott's domestic contract pharmaceutical manufacturing business unit.

Halo offers contract manufacturing, earlystage formulation development, and laboratory services to the pharmaceutical and related industries.

Media **POOL**

Amy Clarke **LUCHSINGER**

Wolters Kluwer Health Names Sales VP for Lippincott Journals

Wolters Kluwer Health has appointed



The most comprehensive online directory of products and services for the life-sciences industry — featuring a wide range of products, services, and solutions for your clinical, commercial, business, and technology needs.

Browse by Category • Search by Company

TALENT pool

Amy Clarke Luchsinger VP of sales, with responsibility for overseeing sales, promotion, and marketing efforts for the Lippincott Williams & Wilkins line of medical and health sciences journals.

Ms. Luchsinger previously served as senior VP of Quadrant HealthCom.

Wolters Kluwer Health provides information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, pharmacy, and the pharmaceutical industry.

Service **POOL**

Dr. Srinivas **AKKARAJU**

NLV Partners Names West Coast Director

New Leaf Venture Partners (NLV Partners), a life science-dedicated venture capital firm, has appointed Srinivas Akkaraju, M.D.,

Ph.D., as managing director and lead of NLV Partners' West Coast biopharmaceuticals practice in Menlo Park, Calif.

Dr. Akkaraju has more than 11 years of experience in life-sciences investing and business development. Before joining NLV Partners, Dr. Akkaraju was a cofounder and managing director of Panorama Capital.

He received an M.D. and a Ph.D. in immunology from Stanford University School of Medicine.

Susan **EDWARDS** Craiq **PYNE**

Datatrial Bolsters North American Presence

As part of an ongoing initiative to expand its footprint and strengthen its data management resources within North America, clinical data solutions and services provider Datatrial has added key personnel and moved to a larger office space in Raleigh, N.C.

Susan Edwards, manager of study delivery based at Datatrial's U.K. headquarters, has been relocated to Raleigh to help the office meet the increased demand from U.S.-based clients.

Datatrial also has hired Craig Pyne as general manager responsible for overseeing the growth of the new office in the United States and helping to reinforce the company's global team.

Most recently, Mr. Pyne was a consultant to companies looking to improve their customer experience and service.

Richard **MICALI**

New Sales VP at PDI

PDI, a provider of contract sales and commercialization services to the biopharmaceutical industry, has named Richard Micali as senior VP of sales services.

Before joining PDI, Mr. Micali was a 25-

May 3 - 5,2009

Renaissance Shanghai Pudong Hotel • Shanghai, China

Business, Legal and Regulatory Developments in the Chinese Pharmaceutical Industry

Whether you represent a major MNC, a biotech, a specialty pharma, a CRO, CMO, or law firm, Impact China is the one event that will cover all the issues and challenges of doing business in China. For 2009, we are expanding the scope of Impact China to look more deeply at recent changes to Chinese intellectual property laws and regulatory updates. Designed for a global audience, Impact China V is your best opportunity to understand the benefits and obstacles of doing business in the region. Come meet new faces, reconnect with old friends and develop your next round of partnerships, joint ventures and profitable deals!

TO REGISTER OR FOR MORE INFORMATION: 212-457-7905 | www.iplawandbusiness.com/china

When registering use priority code: PVAD

For more information on the program, please contact Judy Kelly at 212-457-7926 or Judy. Kelly@incisivemedia.com For sponsorship opportunities, please contact Rob Hafiz at 651-337-0411 or Rob.Hafiz@incisivemedia.com



FINNEGAN

Media Partner:











LAW JOURNAL New York Law Tournal

An incisive media event

ACRP2009

GLOBAL CONFERENCE & EXHIBITION with the APPI Physicians Program

April 24-28, 2009 • Denver, Colorado, USA • www.acrp2009.org





REGISTER TODAY FOR THE

Must-Attend Conference in 2009 for Clinical Research Professionals

In today's economic environment, the Association of Clinical Research Professionals (ACRP) is more determined than ever to provide a value-driven, high quality education conference for clinical research professionals. The ACRP 2009 Global Conference & Exhibition is designed for the entire clinical research team — from senior executives and managers to the front line investigators, clinical research associates (CRAs/Monitors), and clinical research coordinators (CRCs) — in pharmaceutical, biotechnology, medical device, hospital, academic medical center, and physician practice settings.

Be Inspired by These Remarkable Keynote Speakers



Jonathan B. Perlin, MD, PhD, MSHA, FACP

President, Clinical Services and Chief Medical Officer, Hospital Corporation of America, Inc. (HCA)

Healthcare 2019: Health, Technology, Value, and the Opportunity for a Learning Health System

r. Perlin is responsible for clinical strategy and continually improving performance at HCA's approximately 180 hospitals and 80 outpatient centers.

Before joining HCA in 2006, Dr. Perlin was Under Secretary for Health in the U.S. Department of Veterans Affairs. As the Chief Executive Officer of the Veterans Health Administration (VHA), Dr. Perlin led the nation's largest integrated health system. He directed the provision of care to more than 5.3 million patients annually by more than 200,000 healthcare professionals at 1,400 sites, including hospitals, clinics, nursing homes, counseling centers and other facilities. A champion for implementation of electronic health records, Dr. Perlin led VHA performance to international and domestic recognition.



Eva Mozes-Kor

Ethics in Medicine and Research: Lessons from Dr. Mengele

va Mozes and her family were deported to Auschwitz Concentration Camp in 1944. On the selection platform at Auschwitz, Eva and her sister Miriam were identified as twins and taken to join other twins who were to become part of Dr. Josef Mengele's medical experiments. As twins, they were seen as nature's natural guinea pigs. One child was used as a control and the other had experiments conducted on her/him. If a twin died, the other twin was killed by an injection into the heart and comparative autopsies were done on the two.

Today Eva devotes much of her time to speaking about what happened to her and to serving the C.A.N.D.L.E.S. Holocaust Museum and Education center which she founded.

The ACRP Monday Plenary Session is sponsored by





Bert A. Spilker, PhD, MD, FCP, FFPM

r. Spilker, is an independent consultant who was most recently the Senior Vice President of Scientific and Regulatory Affairs for PhRMA (Pharmaceutical Research and Manufacturers of America) based in Washington, D.C.

He was President and cofounder (in 1993) of Orphan Medical, Inc., a public pharmaceutical company that develops and markets important medical products for patients with uncommon diseases. He is well known as the author of 15 books on clinical trial methods and the processes of drug discovery and development. These books are considered by many as the standard references on clinical trials and drug development.

He has worked at four major pharmaceutical companies for over 20 years (Pfizer, Philips-Duphar, Sterling-Winthrop, and Burroughs Wellcome) in medicine discovery, development, and management.

HOT TOPICS!

Don't miss these 15 innovative sessions and workshops designated as **HOT TOPICS** by the ACRP 2009 Global Conference Planning Committee.

- W023: Pearls and Perils of Pediatric Studies
- S015: Mentoring for Success in Clinical Research: Are You Prepared to be a Mentor?
- SP007: Clinical Trials on Trial: Potential Legal Liability Arising From Clinical Trials
- SP024: Adverse Event Reporting in Medical Device Trials— FDA Panel Discussion
- S032: Civil and Criminal Liability from Clinical Trials: What are the Legal Risks?
- S005: First in Human Trials— Warning—Be Careful at Your Site
- S049: Liposomes as Nanocarriers in Biomedical Research and Medicine
- S058: Global Trial Planning— Determining the Optimum Mix of Countries and Sites
- S072: A Model for Success: Combining Winning Ways to Facilitate Patient Recruitment and Building Site Awareness in the Community
- S090: Clinical Leadership: Exploring New Strategies for Service and Professionalization
- S086: The Genetic Information Non-Discrimination Act (GINA)
- SP094: Monitoring for Quality: Risk-Based Clinical Monitoring
- **\$112:** Clinical Trial Globalization: Hype vs. Reality
- \$135: Success at the Crossroads:
 The Intersection of CDISC Standards with Research Site Processes
- **\$144:** Conducting Clinical Trials in China: Status and Trends

